ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GSK Gsk Plc

1,775.00
-8.50 (-0.48%)
17 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -8.50 -0.48% 1,775.00 1,771.00 1,771.50 1,779.00 1,764.50 1,773.50 9,685,415 16:35:19
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.80 72.91B
Gsk Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker GSK. The last closing price for Gsk was 1,783.50p. Over the last year, Gsk shares have traded in a share price range of 1,302.60p to 1,820.00p.

Gsk currently has 4,117,033,438 shares in issue. The market capitalisation of Gsk is £72.91 billion. Gsk has a price to earnings ratio (PE ratio) of 14.80.

Gsk Share Discussion Threads

Showing 15151 to 15174 of 33175 messages
Chat Pages: Latest  607  606  605  604  603  602  601  600  599  598  597  596  Older
DateSubjectAuthorDiscuss
25/10/2017
09:46
Well, my NHS (Wales) shingles jab was Zostavax by Sanofi. Sorry !
zingaro
23/10/2017
17:59
2hog - I will ask on Wednesday when I get mine.
zingaro
23/10/2017
17:43
Is that shingles drug the one that the nhs uses now,you have to be 70 to get it as I enquired recently??
2hoggy
23/10/2017
16:17
GSK should definitely be looking at buying Immupharma's lupus drug Lupuzor which finishes Phase 3 in Jan 2018 and seems set to wipe out GSKs lupus drug Benlysta on price, efficacy and safety.
city chappy
23/10/2017
13:35
NICE nod for GSK’s ‘bubble baby syndrome’ gene therapy
philanderer
20/10/2017
23:56
Nice :-)


“We are absolutely thrilled to get to this point because the science behind this vaccine offers tremendous potential for helping patients, protecting them against getting shingles and its complications,” said Dr. Leonard Friedland, vice president for scientific affairs and public health for GSK’s North American vaccines unit.

GSK has been keenly awaiting the FDA’s ruling, eager to get to market a vaccine analysts estimate could reach $1 billion a year in sales by 2022

philanderer
20/10/2017
23:51
Shingrix approved by FDA
romeike
20/10/2017
17:08
I own 30% of these myself. Oops no, got the decimals wrong it should be .03%, or maybe .003%
jadeticl3
20/10/2017
15:53
Thanks, anhar ... that explains it nicely!
tradermichael
20/10/2017
15:35
The explanation for the ostensibly very low institutional holdings is that the evidence presented covers only US inst. holders who are only a small minority of the total inst. holders since GSK is a Brit company. So that report is worthless for identifying the overall level of institutional trading in GSK shares and therefore useless for drawing any conclusions from it.

Not that knowing inst. trading is of any use anyway as a guide to the merits of the shares.

anhar
20/10/2017
14:31
GSK will announce their third quarter 2017 results on Wednesday 25 October at 12pm BST (7am EST) - you can register for the webcast on
tradermichael
20/10/2017
12:45
...must be!
alphorn
20/10/2017
11:56
Blackrock alone holds 6.66%. There is a typo, obviously.
grahamite2
20/10/2017
11:51
So little private investors own 90%+ of glaxo !! Something very wrong there!
mattboxy
20/10/2017
11:36
The figures are as reported in the last quarter's SEC 13F filings
tradermichael
20/10/2017
11:31
Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares.

I find that very hard to believe. Surely something like 69.34% or 79.34% is more likely?

grahamite2
20/10/2017
09:05
There are a lot of automated websites about giving the sort of info above. I find it makes it harder to get proper news. Many seem to describe the daily share price movements..I wonder how they make money
dr biotech
20/10/2017
09:01
Never had the jab .... never had 'flu.

Anyway,

Recent insider trends for GlaxoSmithKline plc (NYSE:GSK) have caught the attention of investors. Patters in insider activity can help analysts formulate an outlook for a stock. In the case of GSK, the data has a lot to say about how the stock might perform going forward.

Institutions own 09.34% of GlaxoSmithKline plc (GSK)’s shares. The total value of these holdings, in millions, is $9,389. Among active positions in the latest quarter, 343 holders increased their positions by a total of 22.86 million shares, 332 holders decreased the positions by a total of 14.11 million shares, and 161 holders held their positions. This works out to a net increase in ownership of 8.74 million shares, and suggests that institutions are feeling bullish about the stock.

Among new and sold out positions, 64 holders initiated new positions by a total of 2.82 million shares and 62 holders exited their positions by a total of 1.4 million shares. This nets out to an increase of 1.41 million shares and is a bullish sign for GSK.

tradermichael
19/10/2017
19:14
Had the jab every year for six years, not had flu since
romeike
19/10/2017
16:13
Heading to test 1550p, then onwards & upwards
ny boy
19/10/2017
12:37
Had the flu jab. Hoping the outlook this winter is better than some anticipate.

NHS workers now need to sign a form giving reasons, if they refuse vaccination.

essentialinvestor
19/10/2017
08:16
LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that the World Health Organization has awarded pre-qualification for a new four-dose vial version of its Synflorix vaccine for pneumococcal disease in infants and children.

This pre-qualification is mainly for countries that receive support from Gavi, an organisation that seeks to improve access to vaccines for children in, and is aimed at ensuring that vaccines secured through UNICEF for national immunization in low and middle income countries are appropriately safe and effective.

This follows on from a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use.

The formulation of the vaccine has been developed to specifically address cold-chain and storage challenges faced in some areas of the world, Glaxo said.

"Today's WHO pre-qualification for our Synflorix four-dose vial is an important step in helping to ensure children under the age of five in developing countries are protected against this deadly disease. Since 2009, we have delivered more than 500 million doses of this critical pneumococcal vaccine. Through this presentation, we are committed to expanding access to children in Gavi countries where the need is greatest," said Glaxo Vaccines Chief Medical Officer Thomas Breuer.

tradermichael
18/10/2017
13:54
'GSK, Plasticell sign deal to produce haematopoietic cells'
philanderer
18/10/2017
08:37
Shingrix will reach blockbuster status by 2022....... ;0)
tradermichael
Chat Pages: Latest  607  606  605  604  603  602  601  600  599  598  597  596  Older